Borregaard ASA

Borregaard ASA, during a special call, reiterated its full-year sales volume outlook for BioSolutions at approximately 330,000 tonnes, with Q3 volumes anticipated to match Q3 2024 levels, and noted a limited positive effect from vanillin anti-dumping duties. The company also confirmed it would address the temporary production disruption in specialty cellulose at its Sarpsborg facility, previously disclosed in a September 15 Stock Exchange release.

Analysis

Borregaard ASA's special investor call reiterated its full-year sales volume guidance for the BioSolutions division, holding it steady at approximately 330,000 tonnes, which provides a degree of stability for a key segment. For the third quarter, sales volumes in this division are projected to be largely in line with the 81,000 tonnes recorded in the prior year's corresponding quarter. While the company anticipates a positive, albeit limited, financial effect from antidumping duties on vanillin, a significant point of uncertainty was also highlighted. Management acknowledged a temporary production disruption in specialty cellulose at its Sarpsborg, Norway facility, as disclosed in a September 15 stock exchange release. Crucially, the call did not yet provide specific details on the duration or financial impact of this disruption, leaving a critical variable unquantified for the BioMaterials segment's performance and introducing a counterbalancing risk to the otherwise stable outlook.

Key Decisions for Investors

• Investors should closely monitor subsequent company disclosures for the quantified financial and production volume impact of the temporary disruption at the Sarpsborg specialty cellulose facility, as this represents the most significant near-term risk.
• The reaffirmed BioSolutions annual sales volume guidance of 330,000 tonnes and the Q3 estimate of approximately 81,000 tonnes can be used to solidify near-term revenue models for that segment.
• Factor in only a modest uplift from vanillin antidumping duties, as management has explicitly guided for a 'limited effect', cautioning against overestimating its contribution to profitability.